The Independent Standard for Pharmaceutical Reimbursement Risk
A Committee-Based Rating System Calibrated to Historical HTA Outcomes Across US, EU4, UK and Japan.
What MARA Rating Provides
MARA Rating is an independent, standardized assessment of pharmaceutical market access risk.
Regulatory approval does not guarantee reimbursement.
HTA agencies and payers act as a second gate.
MARA synthesizes evidence across 10 payer-relevant domains — including comparative effectiveness, safety, cost-effectiveness, budget impact, and evidence strength — into a single, comparable rating band (A++ to C).
The objective is not to replace judgment.
It is to reduce variance, surface hidden constraints, and provide a defensible benchmark before capital is committed.
How the MARA Rating Is Determined
Structured evaluation across 10 calibrated domains
Public, verifiable evidence sources only
Committee-based judgment; no single analyst determines outcome
Minutes recorded and conflict-of-interest controls enforced
Calibrated against historical HTA outcomes
Subject to defined surveillance and rating actions
Used in High-Stakes Decision Contexts
MARA Ratings are designed to support:
Pre-deal due diligence and valuation stress-testing
Phase 2 → Phase 3 investment decisions
Pre-launch pricing and reimbursement governance
Portfolio reprioritization
Investor memoranda and capital allocation discussions
Core principle:
If this decision is challenged later, what independent reimbursement benchmark was relied upon?
Rating Products
Single-Asset MARA Rating (Internal Use License)
Full committee-based rating with drivers, rationale, benchmarking, and surveillance status.
Therapeutic Area Benchmark Pack
Side-by-side rating comparison across assets within a defined therapeutic area.
Portfolio Access (Institutional License)
Structured access to multiple ratings and rating updates across defined asset groups.
Note: Public display of a MARA Rating requires a valid Display License.
Governance & Calibration
Published methodology framework
Defined rating action categories
Committee charter and conflict-of-interest controls
Calibration against retrospective HTA outcomes
Ongoing surveillance and periodic review
Rating Committee Charter
Annual Calibration Process
Obtain an independent reimbursement risk benchmark.
Methodology Overview (2 Minutes)
This short overview explains the structured evaluation process, committee governance, and calibration principles underlying the MARA Rating.
Check out our Youtube channel here.
Contact a MARA Analyst
Have a molecule in mind—or just a market access pharma question? Send us a note to sales@mararating.com and one of our analysts will reply within one business day. All inquiries are confidential.
"*" indicates required fields
Market Access & Capital Risk Insights
Surveillance Update: Baxdrostat Affirmed at B+ Following April 2026 Review
In HTA-driven environments, stability in reimbursement positioning often reflects persistence of structural constraints rather than absence of progress. Following a
April 2026 MARA Rating Actions
1. Executive Summary During April 2026, MARA issued 12 rating actions across multiple therapeutic areas. The monthly distribution was concentrated
UCB, betting on seizure cell therapy, to buy Neurona for up to $1.2B: what does it mean for Market Access?
UCB Expands Into Regenerative Medicine with $1.2B Acquisition of Neurona Therapeutics Summary Belgian drug company UCB has announced its acquisition
Gilead continues M&A surge with $3.1B deal for ADC specialist Tubulis: what does it mean for Market Access?
Summary Gilead Sciences has announced its acquisition of German biotechnology startup Tubulis for $3.15 billion upfront and a potential additional
White House seeks 12% cut to HHS in 2027: what does it mean for Market Access?
#MarketAccessRiskAssessment #Pricing #Reimbursement #MarketAccess #MARArating #Company #Drug White House seeks 12% cut to HHS in 2027 Summary The White House
MARA Surveillance Update: Forthcoming Reimbursement Risk Assessments Across 12 Assets
Executive Summary MARA is currently finalizing a series of reimbursement risk assessments across twelve drug–indication pairs spanning oncology, rare diseases,